Photograph showing test tubes in research for the Mayo Clinic Multiple Myeloma SPORE Expanding options in multiple myeloma care

SPORE investigators are gaining a better understanding of the genetic and biological mechanisms that drive the growth of multiple myeloma.

Overview

The Mayo Clinic Multiple Myeloma SPORE aims to improve treatment for patients with multiple myeloma and to advance scientific understanding about the mechanisms of disease initiation, progression and relapse.

The Multiple Myeloma SPORE conducts four major translational research projects and offers core resources to support investigators. Through its Developmental Research Program and Career Enhancement Program, the SPORE funds and encourages translational research and the next generation of scientists. The SPORE is part of the Hematologic Malignancies Program, a formal research program within Mayo Clinic Cancer Center that conducts research about cancers of the blood and bone marrow.

The Multiple Myeloma SPORE uses an interdisciplinary approach to achieve its research objectives. It brings together researchers with expertise in basic, applied and clinical science from all three Mayo Clinic campuses in Arizona, Florida and Minnesota. Together, these investigators have published more than 1,500 journal articles related to multiple myeloma. Mayo Clinic SPORE investigators are recognized as leaders in their field. They work together as a team and collaborate with investigators from multiple myeloma SPOREs at other institutions to improve outcomes for patients.

Read more about our research projects:

Patient advocate

Renowned journalist and Mayo Clinic trustee Tom Brokaw serves as the patient advocate to the SPORE, representing the interests of patients with multiple myeloma and increasing awareness of and support for research on multiple myeloma.

Funding

The Mayo Clinic Multiple Myeloma SPORE is funded by the National Cancer Institute (NCI), which awarded Mayo Clinic a five-year, $11.5 million grant in September 2015. A SPORE, or Specialized Program of Research Excellence, is a cornerstone of the NCI's efforts to promote collaborative, interdisciplinary translational cancer research.

Principal investigator

The principal investigator for the Mayo Clinic Multiple Myeloma SPORE is Leif Bergsagel, M.D, an oncologist at Mayo Clinic in Phoenix, Arizona, and a professor of medicine at Mayo Clinic College of Medicine and Science.